dievini Hopp BioTech holding GmbH & Co. KG
  • Welcome
  • Management
  • Portfolio
  • News
  • Imprint
  • Data Protection
  • Deutsch
dievini Hopp BioTech holding GmbH & Co. KG
  • Welcome
  • Management
  • Portfolio
  • News
  • Imprint
  • Data Protection
  • Deutsch

November 1, 2021: Immatics Biotechnologies GmbH

Immatics to Present Update on Lead ACTengine® Program IMA203 Targeting PRAME at the Society for Immunotherapy of Cancer’s 36th Annual Meeting

Immatics N.V. (“Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, today announced that the company will provide an update on its ACTengine® IMA203 trial in a late-breaking oral presentation as well as an update on Immatics’ next-generation CD8ab TCR-T approach at the 36th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC). The Conference will take place, both in person and virtually, from November 10 – 14, 2021.

Please read the whole article here

Immatics Biotechnologies GmbH, News 2021
October 29, 2021: AC Immune SA
November 2, 2021: AC Immune SA

dievini Hopp BioTech holding GmbH & Co. KG | Impressum | Datenschutz